Developer docs
API playgroundTry for free, no card

Search company profiles

Zelgen

Full company profile

uuid0005w2n

Namestring
Zelgen
Legal namestring
苏州泽璟生物制药股份有限公司
Websiteurl
zelgen.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Zelgen (Suzhou Zelgen Biopharmaceuticals Co., Ltd., Shanghai Stock Exchange: 688266) is a publicly listed Chinese biopharmaceutical company founded in 2009 and headquartered in Kunshan, Jiangsu Province, with 501-1,000 employees. The company develops and commercializes innovative drugs across three therapeutic areas: oncology (notably hepatocellular carcinoma and small cell lung cancer), hematology and immunology (myelofibrosis and autoimmune inflammatory diseases such as severe alopecia areata and atopic dermatitis), and hemostasis/diagnostics. It currently markets four NMPA-approved drugs: Zepsun (donafenib tosylate, China's first domestically developed multi-targeted TKI for first-line advanced HCC, approved June 2021 and also indicated for radioactive iodine-refractory differentiated thyroid cancer); Zepuning (recombinant human thrombin, the only recombinant human thrombin commercialized in China, approved January 2024); Zepuping (gecacitinib hydrochloride, China's first domestically developed JAK inhibitor, approved May 2025 for myelofibrosis and June 2026 for severe alopecia areata); and Zesuning (recombinant human thyrotropin beta, China's first approved diagnostic for postoperative DTC assessment, approved January 2026).

Zelgen operates two parallel R&D engines. The small-molecule drug R&D platform integrates drug stabilization technology, structure-activity relationship screening, and AI-aided drug design including deep QSAR modeling and generative molecule generation, and has produced Zepsun, Zepuning, ZG2001 (a pan-KRAS SOS1 inhibitor with dual NMPA/FDA IND clearance), and ZG0895 (a TLR8 agonist with dual NMPA/FDA IND clearance). The bispecific and trispecific antibody platform, housed in majority-owned US subsidiary Gensun Biopharma Inc. (51%), consists of three proprietary architectures - TriGen (trispecific antibodies, source of ZG006/Alveltamig, the world's first DLL3-targeting trispecific), CheckGen (immune checkpoint bispecifics), and TGen (novel-target bispecifics, source of ZG005/Nilvanstomig, a PD-1/TIGIT bispecific). The complex recombinant protein platform underpins Zepuning and Zesuning. Manufacturing is conducted at GMP-compliant facilities in Kunshan covering 11,000 sqm of oral solid tablet capacity and 4,000 sqm of recombinant protein capacity. The intellectual property estate stands at 390 patent applications filed and 136 patents granted across China, the US, the EU and other jurisdictions as of September 2025.

Commercially, Zelgen combines direct field sales (market directors, regional promotion managers, medical science liaisons, sales management) with exclusive territory-based distribution partnerships: Yuanda Life Sciences for Zepuning in Greater China (December 2023) and ATSA, a Swiss affiliate of Merck, for Zesuning in Mainland China (June 2025). The company has secured NRDL inclusion for Zepsun, Zepuning (effective January 2025) and Zepuping (effective January 2026), positioning each for broad hospital and pharmacy access. Revenue also includes licensing income, most notably the December 2025 strategic collaboration and option-to-license agreement with AbbVie granting AbbVie exclusive global rights outside Greater China to ZG006, plus CDMO-related revenue from a long-term cooperation with Pulo Pharmaceutical. The company previously completed a 2018 Series 2 financing of approximately $62M and listed on the Shanghai Stock Exchange STAR Market in 2020.

Short descriptiontext

Zelgen (Suzhou Zelgen Biopharmaceuticals) is a Chinese biopharma company that has commercialized four innovative drugs in oncology, hematology, autoimmune disease, and hemostasis/diagnostics, supported by proprietary small-molecule and bispecific/trispecific antibody R&D platforms including the world's first DLL3-targeting trispecific antibody partnered with AbbVie.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKunshan, China
HQ citystring
Kunshan
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
innovative oncology drugs, small molecule therapeutics, bispecific antibodies, autoimmune disease treatments, recombinant protein drugs
Industry4 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals / Oncology and Hematology Drugs
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical product sales
TypeOne Time License
Description

Zelgen generates revenue from the sale of its four commercialized innovative drugs: Zepsun (Donafenib Tosilate Tablets) for hepatocellular carcinoma, Zepuping (Gecacitinib Hydrochloride Tablets) for myelofibrosis, Zepuning (Recombinant Human Thrombin) for hemostasis, and Zesuning (Human Thyrotropin beta) for differentiated thyroid cancer diagnosis. Sales are made directly through commercial teams and via exclusive distribution partners in specific territories.

zelgen.com
2Licensing and partnership revenue
TypeLicensing Royalties
Description

Zelgen receives licensing revenue from strategic partnerships such as the AbbVie agreement for ZG006 (Alveltamig), where AbbVie obtained exclusive rights outside Greater China. The company also licenses patent rights to third parties (e.g., Gensun license to Qilu Pharmaceutical for GS02, to Kintor for GS19).

zelgen.com
3CDMO and contract manufacturing
TypeProfessional Services
Description

Zelgen provides contract development and manufacturing services through partnerships such as the strategic cooperation with Pulo Pharmaceutical for API and intermediate R&D and custom manufacturing.

zelgen.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Zelgen develops, manufactures, and commercializes innovative small-molecule and biologic drugs for oncology, hematology, autoimmune and inflammatory diseases, and hemostasis/diagnostics. Four marketed products are sold in China: Zepsun (donafenib) for HCC and thyroid cancer, Zepuping (gecacitinib) for myelofibrosis and alopecia areata, Zepuning (recombinant human thrombin) for surgical hemostasis, and Zesuning (human thyrotropin beta) for thyroid cancer postoperative assessment. A pipeline of 10+ clinical-stage candidates targets solid tumors, autoimmune diseases, and previously undruggable oncogenic pathways.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Zepsun Phase III (ZGDH3): mOS 12.1 vs 10.3 months for sorafenib (HR=0.831, p=0.0363) in first-line advanced HCC; only monotherapy to demonstrate superior survival vs sorafenib in head-to-head HCC trial
+6 more records
Product overview1 text field

Zelgen is an innovation-driven biopharmaceutical company with four commercially marketed drugs: Zepsun® (donafenib tosylate) for hepatocellular carcinoma and thyroid cancer; Zepuping® (gecacitinib hydrochloride) for myelofibrosis with expansion into autoimmune diseases; Zepuning® (recombinant human thrombin) for surgical hemostasis; and Zesuning® (human thyrotropin beta) for thyroid cancer diagnosis. The company operates dual innovation engines combining a small-molecule drug R&D platform with AI-aided design capabilities and a bispecific/trispecific antibody platform (TriGen, CheckGen, TGen) plus complex recombinant protein platform. The pipeline includes 10+ candidates with best-in-class/first-in-class potential, including ZG006 (Alveltamig) - world's first DLL3-targeting trispecific antibody, and ZG005 (Nilvanstomig) - PD-1/TIGIT bispecific antibody. Zelgen has established commercial GMP manufacturing facilities for both oral solid tablets and recombinant proteins in Kunshan, China.

Product and service3 records
1Zepsun (泽普生) — Donafenib Tosilate Tablets
CategoryMarketed Small-Molecule Oncology Drug
Description

Oral multi-targeted tyrosine kinase inhibitor (targets VEGFR, PDGFR, Raf kinases) for first-line treatment of advanced hepatocellular carcinoma and progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. Sold to Chinese hospitals and pharmacies for patient administration.

2Zepuping (泽普平) — Gecacitinib Hydrochloride Tablets
CategoryMarketed Small-Molecule Immunology/Hematology Drug
Description

Novel JAK inhibitor targeting JAK1, JAK2, JAK3 and TYK2 with dual JAK/ACVR1 activity. Approved in China for intermediate-2/high-risk myelofibrosis and severe alopecia areata in adults; under development for additional autoimmune indications including atopic dermatitis and ankylosing spondylitis.

3Zepuning (泽普凝) — Recombinant Human Thrombin
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

In May 2026, Zelgen and Merck R&D China Innovation Collaboration Center (MCICC) reached a clinical strategic cooperation intention for joint development of tumor trispecific antibody drugs. Both parties will integrate their respective strengths to accelerate clinical development in solid tumors, leveraging Merck's global clinical development and oncology immuno expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-02
Description

In December 2025, Zelgen entered into a strategic collaboration and option-to-license agreement with AbbVie for global development and commercialization of ZG006 (Alveltamig). AbbVie obtained exclusive rights outside Greater China (Mainland China, Hong Kong SAR, Macau SAR), while Zelgen retained development and commercialization rights within Greater China. ZG006 is a DLL3-targeting trispecific T-cell engager for SCLC and other neuroendocrine tumors.

3ATSA (Merck Swiss affiliate)
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-01
Description

In June 2025, Zelgen signed an exclusive sales distribution agreement with ATSA, a Swiss affiliate of Merck, granting exclusive rights to promote and market Zesuning (Human Thyrotropin beta) in Mainland China.

zelgen.com
4Yuanda Life Sciences (Shandong) Co., Ltd. (远大生命科学(山东)有限公司)
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-01
Description

In December 2023, Zelgen entered into an exclusive sales distribution agreement with Yuanda Life Sciences, granting exclusive rights to promote and market Zepuning (Recombinant Human Thrombin) in Mainland China, Hong Kong, Macau, and Taiwan region.

zelgen.com
5Pulo Pharmaceutical Co., Ltd. (普洛药业股份有限公司, Stock: 000739.SZ)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-06-13
Description

Zelgen signed a strategic cooperation framework agreement with Pulo Pharmaceutical for long-term cooperation in API and intermediate R&D and custom manufacturing (CDMO) projects. Pulo Pharma has advanced manufacturing facilities, R&D capabilities, quality management, and EHS control systems, serving as a one-stop professional R&D and manufacturing service provider for global innovative drug clients.

zelgen.com
6Kintor Pharmaceutical Limited (开拓药业, Stock: 9939.HK)
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-08-21
Description

Subsidiary Gensun licensed GS19 (PD-L1/TGF-beta bispecific antibody) to Kintor Pharmaceutical for exclusive development and commercialization in Greater China. Gensun received $23 million in upfront and milestone payments plus royalties on net sales.

zelgen.com
7Gensun Biopharma Inc. (泽璟控股51%)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-17
Description

Gensun is Zelgen's majority-owned subsidiary (51% fully diluted) based in California, USA. Gensun operates three proprietary bispecific/trispecific antibody platforms (TriGen, CheckGen, TGen) and has generated multiple clinical-stage bispecific/trispecific antibody candidates including ZG005, ZG006, ZGGS18, ZGGS15. Gensun has 10+ preclinical projects and has granted patent licenses to Qilu Pharmaceutical and Kintor Pharmaceutical.

zelgen.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading Chinese biotech with a strong oncology and immunology pipeline including PD-1 (sintilimab) and multiple bispecific antibodies. Directly comparable to Zelgen as a domestic innovative-drug company combining small molecules, biologics, and bispecifics, with commercial launches and global BD partnerships.

TypeDirect peer
Description

Chinese biotech specializing in bispecific and multispecific antibodies (e.g., PD-1/VEGF cadonilimab). Closely comparable to Zelgen on the bispecific/trispecific antibody platform thesis and oncology focus, with multiple Phase III assets and rising global profile.

TypeBroad incumbent
Description

Large global Chinese biopharma with the BTK inhibitor zanubrutinib and PD-1 tislelizumab. Comparable as a broader Chinese oncology platform with both small molecules and biologics, global commercial footprint, and an innovation engine of similar scale to Zelgen.

TypeDirect peer
Description

Chinese biotech with toripalimab (PD-1) and a pipeline of bispecifics. Comparable to Zelgen on the innovation-stage domestic biotech profile, NRDL/regulatory navigation, and emerging bispecific pipeline development.

5Hansoh Pharmaceutical
TypeBroad incumbent
Description

One of China's largest domestic innovative pharma companies with multiple launched innovative drugs across oncology, CNS, and metabolic disease. Comparable as a Chinese peer with both small-molecule and biologic capabilities and a focus on NRDL-driven commercialization.

6Hutchmed (HUTCHMED)
TypeDirect peer
Description

Hong Kong-headquartered Chinese oncology biotech with surufatinib, savolitinib, and fruquintinib. Comparable as an innovative Chinese oncology company pursuing global development through partnerships (AstraZeneca, Takeda, Eli Lilly) — a similar playbook to Zelgen's AbbVie deal.

TypeDirect peer
Description

Chinese biotech with the first domestic HER2 ADC (disitamab vedotin) and bispecific antibodies. Comparable to Zelgen on the antibody platform thesis, oncology focus, and Chinese innovative-drug commercialization with global BD potential.

TypeDirect peer
Description

Chinese oncology biotech with PD-L1 (sugemalimab) and multiple targeted therapies, with established global partnerships (Pfizer, EQRx). Comparable to Zelgen on the China-innovator + global-BD business model for oncology assets.

9Shanghai Henlius Biotech
TypeRegional player
Description

Chinese biopharma with a biosimilars and biologics platform, multiple approved products, and strong GMP manufacturing. Comparable to Zelgen on the biologics manufacturing and complex recombinant protein capabilities (e.g., Zepuning and Zesuning).

TypeBroad incumbent
Description

Global biopharma with tarlatamab, a leading DLL3-directed BiTE in small cell lung cancer. Relevant to Zelgen as the principal global competitor for ZG006 in the DLL3 space and as a benchmark for trispecific/multispecific T-cell engager development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zelgen

Biopharmaceuticals / Oncology and Hematology Drugszelgen.com

Zelgen (Suzhou Zelgen Biopharmaceuticals) is a Chinese biopharma company that has commercialized four innovative drugs in oncology, hematology, autoimmune disease, and hemostasis/diagnostics, supported by proprietary small-molecule and bispecific/trispecific antibody R&D platforms including the world's first DLL3-targeting trispecific antibody partnered with AbbVie.

What Zelgen does

Zelgen (Suzhou Zelgen Biopharmaceuticals Co., Ltd., Shanghai Stock Exchange: 688266) is a publicly listed Chinese biopharmaceutical company founded in 2009 and headquartered in Kunshan, Jiangsu Province, with 501-1,000 employees. The company develops and commercializes innovative drugs across three therapeutic areas: oncology (notably hepatocellular carcinoma and small cell lung cancer), hematology and immunology (myelofibrosis and autoimmune inflammatory diseases such as severe alopecia areata and atopic dermatitis), and hemostasis/diagnostics. It currently markets four NMPA-approved drugs: Zepsun (donafenib tosylate, China's first domestically developed multi-targeted TKI for first-line advanced HCC, approved June 2021 and also indicated for radioactive iodine-refractory differentiated thyroid cancer); Zepuning (recombinant human thrombin, the only recombinant human thrombin commercialized in China, approved January 2024); Zepuping (gecacitinib hydrochloride, China's first domestically developed JAK inhibitor, approved May 2025 for myelofibrosis and June 2026 for severe alopecia areata); and Zesuning (recombinant human thyrotropin beta, China's first approved diagnostic for postoperative DTC assessment, approved January 2026).

Zelgen operates two parallel R&D engines. The small-molecule drug R&D platform integrates drug stabilization technology, structure-activity relationship screening, and AI-aided drug design including deep QSAR modeling and generative molecule generation, and has produced Zepsun, Zepuning, ZG2001 (a pan-KRAS SOS1 inhibitor with dual NMPA/FDA IND clearance), and ZG0895 (a TLR8 agonist with dual NMPA/FDA IND clearance). The bispecific and trispecific antibody platform, housed in majority-owned US subsidiary Gensun Biopharma Inc. (51%), consists of three proprietary architectures - TriGen (trispecific antibodies, source of ZG006/Alveltamig, the world's first DLL3-targeting trispecific), CheckGen (immune checkpoint bispecifics), and TGen (novel-target bispecifics, source of ZG005/Nilvanstomig, a PD-1/TIGIT bispecific). The complex recombinant protein platform underpins Zepuning and Zesuning. Manufacturing is conducted at GMP-compliant facilities in Kunshan covering 11,000 sqm of oral solid tablet capacity and 4,000 sqm of recombinant protein capacity. The intellectual property estate stands at 390 patent applications filed and 136 patents granted across China, the US, the EU and other jurisdictions as of September 2025.

Commercially, Zelgen combines direct field sales (market directors, regional promotion managers, medical science liaisons, sales management) with exclusive territory-based distribution partnerships: Yuanda Life Sciences for Zepuning in Greater China (December 2023) and ATSA, a Swiss affiliate of Merck, for Zesuning in Mainland China (June 2025). The company has secured NRDL inclusion for Zepsun, Zepuning (effective January 2025) and Zepuping (effective January 2026), positioning each for broad hospital and pharmacy access. Revenue also includes licensing income, most notably the December 2025 strategic collaboration and option-to-license agreement with AbbVie granting AbbVie exclusive global rights outside Greater China to ZG006, plus CDMO-related revenue from a long-term cooperation with Pulo Pharmaceutical. The company previously completed a 2018 Series 2 financing of approximately $62M and listed on the Shanghai Stock Exchange STAR Market in 2020.

Zelgen firmographics

Firmographics
Name
Zelgen
Legal name
苏州泽璟生物制药股份有限公司
Website
https://zelgen.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Zelgen (Suzhou Zelgen Biopharmaceuticals) is a Chinese biopharma company that has commercialized four innovative drugs in oncology, hematology, autoimmune disease, and hemostasis/diagnostics, supported by proprietary small-molecule and bispecific/trispecific antibody R&D platforms including the world's first DLL3-targeting trispecific antibody partnered with AbbVie.
Ownership category
akta.pro rank

Zelgen industry classification

Industry
Product category
Biopharmaceuticals / Oncology and Hematology Drugs
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Innovative oncology drugs
  • Small molecule therapeutics
  • Bispecific antibodies
  • Autoimmune disease treatments
  • Recombinant protein drugs

Where Zelgen is headquartered

Location

Headquarters

HQ city
Kunshan
HQ country
China
HQ region
Asia

Offices3 records

Markets served

Zelgen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical product sales: Zelgen generates revenue from the sale of its four commercialized innovative drugs: Zepsun (Donafenib Tosilate Tablets) for hepatocellular carcinoma, Zepuping (Gecacitinib Hydrochloride Tablets) for myelofibrosis, Zepuning (Recombinant Human Thrombin) for hemostasis, and Zesuning (Human Thyrotropin beta) for differentiated thyroid cancer diagnosis. Sales are made directly through commercial teams and via exclusive distribution partners in specific territories.
  2. Licensing and partnership revenue: Zelgen receives licensing revenue from strategic partnerships such as the AbbVie agreement for ZG006 (Alveltamig), where AbbVie obtained exclusive rights outside Greater China. The company also licenses patent rights to third parties (e.g., Gensun license to Qilu Pharmaceutical for GS02, to Kintor for GS19).
  3. CDMO and contract manufacturing: Zelgen provides contract development and manufacturing services through partnerships such as the strategic cooperation with Pulo Pharmaceutical for API and intermediate R&D and custom manufacturing.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Zelgen product offering

Product offering

Core offering

Zelgen develops, manufactures, and commercializes innovative small-molecule and biologic drugs for oncology, hematology, autoimmune and inflammatory diseases, and hemostasis/diagnostics. Four marketed products are sold in China: Zepsun (donafenib) for HCC and thyroid cancer, Zepuping (gecacitinib) for myelofibrosis and alopecia areata, Zepuning (recombinant human thrombin) for surgical hemostasis, and Zesuning (human thyrotropin beta) for thyroid cancer postoperative assessment. A pipeline of 10+ clinical-stage candidates targets solid tumors, autoimmune diseases, and previously undruggable oncogenic pathways.

Product overview

Zelgen is an innovation-driven biopharmaceutical company with four commercially marketed drugs: Zepsun® (donafenib tosylate) for hepatocellular carcinoma and thyroid cancer; Zepuping® (gecacitinib hydrochloride) for myelofibrosis with expansion into autoimmune diseases; Zepuning® (recombinant human thrombin) for surgical hemostasis; and Zesuning® (human thyrotropin beta) for thyroid cancer diagnosis. The company operates dual innovation engines combining a small-molecule drug R&D platform with AI-aided design capabilities and a bispecific/trispecific antibody platform (TriGen, CheckGen, TGen) plus complex recombinant protein platform. The pipeline includes 10+ candidates with best-in-class/first-in-class potential, including ZG006 (Alveltamig) - world's first DLL3-targeting trispecific antibody, and ZG005 (Nilvanstomig) - PD-1/TIGIT bispecific antibody. Zelgen has established commercial GMP manufacturing facilities for both oral solid tablets and recombinant proteins in Kunshan, China.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zepsun (泽普生) — Donafenib Tosilate Tablets Oral multi-targeted tyrosine kinase inhibitor (targets VEGFR, PDGFR, Raf kinases) for first-line treatment of advanced hepatocellular carcinoma and progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. Sold to Chinese hospitals and pharmacies for patient administration.
  • Zepuping (泽普平) — Gecacitinib Hydrochloride Tablets Novel JAK inhibitor targeting JAK1, JAK2, JAK3 and TYK2 with dual JAK/ACVR1 activity. Approved in China for intermediate-2/high-risk myelofibrosis and severe alopecia areata in adults; under development for additional autoimmune indications including atopic dermatitis and ankylosing spondylitis.
  • Zepuning (泽普凝) — Recombinant Human Thrombin

Quantifiable outcome

  • Zepsun Phase III (ZGDH3): mOS 12.1 vs 10.3 months for sorafenib (HR=0.831, p=0.0363) in first-line advanced HCC; only monotherapy to demonstrate superior survival vs sorafenib in head-to-head HCC trial
  • +6 more outcomes

Companies that use Zelgen

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Zelgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Zelgen partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and minor.

  • Merck (MSD) R&D (China) Co., Ltd. (默沙东研发(中国)有限公司)coreStrategic or Co-development Partner · 12 May 2026In May 2026, Zelgen and Merck R&D China Innovation Collaboration Center (MCICC) reached a clinical strategic cooperation intention for joint development of tumor trispecific antibody drugs. Both parties will integrate their respective strengths to accelerate clinical development in solid tumors, leveraging Merck's global clinical development and oncology immuno expertise.
  • AbbVie Group Holding Company (registered in Bermuda)coreStrategic or Co-development Partner · 2 December 2025In December 2025, Zelgen entered into a strategic collaboration and option-to-license agreement with AbbVie for global development and commercialization of ZG006 (Alveltamig). AbbVie obtained exclusive rights outside Greater China (Mainland China, Hong Kong SAR, Macau SAR), while Zelgen retained development and commercialization rights within Greater China. ZG006 is a DLL3-targeting trispecific T-cell engager for SCLC and other neuroendocrine tumors.
  • ATSA (Merck Swiss affiliate)majorChannel Partner/ Reseller/ Distributor · 1 June 2025In June 2025, Zelgen signed an exclusive sales distribution agreement with ATSA, a Swiss affiliate of Merck, granting exclusive rights to promote and market Zesuning (Human Thyrotropin beta) in Mainland China.
  • Yuanda Life Sciences (Shandong) Co., Ltd. (远大生命科学(山东)有限公司)majorChannel Partner/ Reseller/ Distributor · 1 December 2023In December 2023, Zelgen entered into an exclusive sales distribution agreement with Yuanda Life Sciences, granting exclusive rights to promote and market Zepuning (Recombinant Human Thrombin) in Mainland China, Hong Kong, Macau, and Taiwan region.
  • Pulo Pharmaceutical Co., Ltd. (普洛药业股份有限公司, Stock: 000739.SZ)majorStrategic or Co-development Partner · 13 June 2023Zelgen signed a strategic cooperation framework agreement with Pulo Pharmaceutical for long-term cooperation in API and intermediate R&D and custom manufacturing (CDMO) projects. Pulo Pharma has advanced manufacturing facilities, R&D capabilities, quality management, and EHS control systems, serving as a one-stop professional R&D and manufacturing service provider for global innovative drug clients.
  • Kintor Pharmaceutical Limited (开拓药业, Stock: 9939.HK)minorOEM/ Whitelabel/ Licensing Partner · 21 August 2020Subsidiary Gensun licensed GS19 (PD-L1/TGF-beta bispecific antibody) to Kintor Pharmaceutical for exclusive development and commercialization in Greater China. Gensun received $23 million in upfront and milestone payments plus royalties on net sales.
  • Gensun Biopharma Inc. (泽璟控股51%)coreStrategic or Co-development Partner · 17 August 2020Gensun is Zelgen's majority-owned subsidiary (51% fully diluted) based in California, USA. Gensun operates three proprietary bispecific/trispecific antibody platforms (TriGen, CheckGen, TGen) and has generated multiple clinical-stage bispecific/trispecific antibody candidates including ZG005, ZG006, ZGGS18, ZGGS15. Gensun has 10+ preclinical projects and has granted patent licenses to Qilu Pharmaceutical and Kintor Pharmaceutical.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Zelgen competitors and assessment

Company assessment

Direct peers

  • Innovent Biologics: Leading Chinese biotech with a strong oncology and immunology pipeline including PD-1 (sintilimab) and multiple bispecific antibodies. Directly comparable to Zelgen as a domestic innovative-drug company combining small molecules, biologics, and bispecifics, with commercial launches and global BD partnerships.
  • Akeso, Inc. Chinese biotech specializing in bispecific and multispecific antibodies (e.g., PD-1/VEGF cadonilimab). Closely comparable to Zelgen on the bispecific/trispecific antibody platform thesis and oncology focus, with multiple Phase III assets and rising global profile.
  • Junshi Biosciences: Chinese biotech with toripalimab (PD-1) and a pipeline of bispecifics. Comparable to Zelgen on the innovation-stage domestic biotech profile, NRDL/regulatory navigation, and emerging bispecific pipeline development.
  • Hutchmed (HUTCHMED): Hong Kong-headquartered Chinese oncology biotech with surufatinib, savolitinib, and fruquintinib. Comparable as an innovative Chinese oncology company pursuing global development through partnerships (AstraZeneca, Takeda, Eli Lilly) — a similar playbook to Zelgen's AbbVie deal.
  • RemeGen: Chinese biotech with the first domestic HER2 ADC (disitamab vedotin) and bispecific antibodies. Comparable to Zelgen on the antibody platform thesis, oncology focus, and Chinese innovative-drug commercialization with global BD potential.
  • Cstone Pharmaceuticals: Chinese oncology biotech with PD-L1 (sugemalimab) and multiple targeted therapies, with established global partnerships (Pfizer, EQRx). Comparable to Zelgen on the China-innovator + global-BD business model for oncology assets.

Broad incumbents

  • BeiGene: Large global Chinese biopharma with the BTK inhibitor zanubrutinib and PD-1 tislelizumab. Comparable as a broader Chinese oncology platform with both small molecules and biologics, global commercial footprint, and an innovation engine of similar scale to Zelgen.
  • Hansoh Pharmaceutical: One of China's largest domestic innovative pharma companies with multiple launched innovative drugs across oncology, CNS, and metabolic disease. Comparable as a Chinese peer with both small-molecule and biologic capabilities and a focus on NRDL-driven commercialization.
  • Amgen: Global biopharma with tarlatamab, a leading DLL3-directed BiTE in small cell lung cancer. Relevant to Zelgen as the principal global competitor for ZG006 in the DLL3 space and as a benchmark for trispecific/multispecific T-cell engager development.

Regional players

  • Shanghai Henlius Biotech: Chinese biopharma with a biosimilars and biologics platform, multiple approved products, and strong GMP manufacturing. Comparable to Zelgen on the biologics manufacturing and complex recombinant protein capabilities (e.g., Zepuning and Zesuning).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Zelgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zelgen leadership team

Management profile

Number of profiles

Profiles1 record

Zelgen subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Zelgen funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zelgen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zelgen

What does Zelgen do?

Zelgen develops, manufactures, and commercializes innovative small-molecule and biologic drugs for oncology, hematology, autoimmune and inflammatory diseases, and hemostasis/diagnostics. Four marketed products are sold in China: Zepsun (donafenib) for HCC and thyroid cancer, Zepuping (gecacitinib) for myelofibrosis and alopecia areata, Zepuning (recombinant human thrombin) for surgical hemostasis, and Zesuning (human thyrotropin beta) for thyroid cancer postoperative assessment. A pipeline of 10+ clinical-stage candidates targets solid tumors, autoimmune diseases, and previously undruggable oncogenic pathways.

Is Zelgen a public or private company?

Zelgen is a public company. It is classified as public and is currently operating.

When was Zelgen founded?

Zelgen was founded in 2009. It employs 11 to 50 people.

Where is Zelgen based?

Zelgen is headquartered in Kunshan, China, in the Asia region.

How does Zelgen make money?

Three revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are licensing and partnership revenue and CDMO and contract manufacturing.

Who are Zelgen's main competitors?

Direct peers on record are Innovent Biologics, Akeso, Inc., Junshi Biosciences, Hutchmed (HUTCHMED), RemeGen and Cstone Pharmaceuticals. Broad incumbents are BeiGene, Hansoh Pharmaceutical and Amgen. Shanghai Henlius Biotech is listed as a regional player.

Does Zelgen have an API?

No public API is recorded for Zelgen.

What industry is Zelgen in?

Zelgen's product category is Biopharmaceuticals / Oncology and Hematology Drugs. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterZelgen Pharma inks licensing option agreement with AbbVieChina's Zelgen Pharma (688266: SH) has entered into a strategic collaboration and license option agreement with US pharma major AbbVie (NYSE: ABBV) for the global development and commercialization of ZG006 (alveltamig). Under the agreement, AbbVie will obtain exclusive rights to develop and commercialize the DLL3-targeting therapy outside Greater China, while Zelgen will retain rights within mainland China, Hong Kong, and Macau. ZG006 is engineered to target DLL3, a protein highly expressed on small-cell lung cancer and other neuroendocrine tumors, while simultaneously recruiting T cells to attack malignant cells.MarketScreenerZelgen Biopharma says it signs strategic partnership with Abbvie for development and commercialisation of AlveltamigZelgen Biopharma has signed a strategic partnership with AbbVie for the development and commercialisation of Alveltamig. The article contains only a title and scraped financial data about AbbVie's company profile, ratings, and analyst consensus, with no substantive details about the partnership terms, timeline, or strategic implications.MarketScreenerZelgen Biopharma says to receive &100 mln upfront payment, additional $1.1 bln in milestone payments if AbbVie exercises license optionZelgen Biopharma announced it will receive a $100 million upfront payment under a licensing agreement, with potential additional milestone payments of up to $1.1 billion if AbbVie exercises its option. The milestone payments would be triggered upon achievement of specified developmental and regulatory milestones. This deal represents a significant non-dilutive capital infusion for Zelgen's pipeline programs.